Home » Posts tagged with » Tagrisso
AstraZeneca gets FDA approval for Tagrisso for type of NSCLC

AstraZeneca gets FDA approval for Tagrisso for type of NSCLC

AstraZeneca has secured extended approval from the US Food and Drug Administration for using Tagrisso (osimertinib) as an adjuvant treatment of non-small cell lung cancer (NSCLC) in patients whose tumors have a certain type of genetic mutation. According to the FDA, nearly 20% of patients with non-small cell lung cancer will have epidermal growth factor […]

December 19, 2020No CommentRead More

Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS

August 11, 2019 No Comment
Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS

Tagrisso FLAURA trial results : Pharma giant AstraZeneca said that the phase 3 FLAURA trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) has yielded positive overall survival (OS) results. The randomized, double-blinded, multicenter late-stage trial featured NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) […]

Continue reading …

AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation

October 15, 2017 No Comment
AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation

Pharma news updates : Tagrisso (osimertinib), the AstraZeneca lung cancer drug has bagged the breakthrough therapy designation (BTD) from the US FDA for the treatment of non-small cell lung cancer (NSCLC) in a first line setting. The BTD designation for the AstraZeneca cancer drug is specifically for treating metastatic NSCLC patients who have tested positive […]

Continue reading …